← Back to Search
Proteases And Their Inhibitors In Cancer Metastasis
R. Ablin, W. Jiang, J. Foidart, R. Muschel, C. Brinckerhoff, U. Benbow, Y. DeClerck, B. Nawrocki-Raby, C. Clavel, M. Polette
Published 2002 ·
Download PDFAnalyze on Scholarcy
Proteinases play a central role in the complex response of tissues to injury by influencing cellular behavior and matrix remodeling. Considerable information on the biology of proteinases has been derived from gene targeting and gene transfer studies. One of the best characterised proteinase systems is the plasminogen system, belonging to the large serine proteinase family. Using mice with a targeted deficiency of plasminogen system components, it has become obvious that the plasminogen system can – directly or indirectly by activation of matrix metalloproteinases – have divergent – even opposite – roles in disease favoring healing in some cases and promoting tissue destruction in others. This Chapter discusses the mechanisms by which the plasminogen system can influence the response to injury in the vessel wall, the heart, the nervous system, the lungs
This paper references
Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism.
N. Maas-Szabowski (1999)
Egr-1 Mediates Extracellular Matrix-driven Transcription of Membrane Type 1 Matrix Metalloproteinase in Endothelium*
T. Haas (1999)
Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense.
C. L. Wilson (1999)
Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22.
A. Lévy (1992)
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).
H. R. Lijnen (1998)
Membrane‐type 1 MMP (MMP‐14) cleaves at three sites in the aggrecan interglobular domain
A. Fosang (1998)
Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma.
C. Linder (1998)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions.
F. Galateau-Sallé (2000)
Tissue Inhibitor of Metalloproteinase‐2 Induces Apoptosis in Human T Lymphocytes
M. Lim (1999)
A labile repressor acts through the NFkB-like binding sites of the human urokinase gene.
U. Novak (1991)
Tumor invasion and the extracellular matrix.
L. Liotta (1983)
Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins
N. Hiraoka (1998)
M. Toyoshima (1999)
A SWI / SNF – Related Chromatin Remodeling Complex , ERC 1 , Is Required for Tissue-Specific Transcriptional Regulation
J. Armstrong (1998)
Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.
H. Emonard (1992)
Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
LA Reiter (2000)
Co-ordinate up-regulation of Sp1 DNA-binding activity and urokinase-receptor expression in breast carcinoma
A Zannetti (2000)
Differential effects of transforming growth factor-β1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts
D. Edwards (1996)
Membrane-Type Matrix Metalloproteinases
M. G. Jiménez (2002)
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
G. Giannelli (1997)
Activation of the precursor of gelatinase A/72 kda type IV collagenase/MMP‐2 in lung carcinomas correlates with the expression of membrane‐type matrix metalloproteinase (MT‐MMP) and with lymph node metastasis
M. Tokuraku (1995)
MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN
R. Babine (1997)
Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells.
I. Saiki (1990)
Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin.
C. L. Wilson (1997)
Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3.
J. Bian (1996)
Transcriptional inactivation of the tissue inhibitor of metalloproteinase‐3 gene by dna hypermethylation of the 5'‐CpG island in human gastric cancer cell lines
S. Kang (2000)
The coordinated regulation of heparan sulfate, syndecans and cell behavior.
A. Rapraeger (1993)
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1.
P. Henriet (2000)
The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
G. Christofori (1999)
Dynamics of basement membrane formation by keratinocyte-fibroblast interactions in organotypic skin culture.
H. Smola (1998)
Regulation of matrix metalloproteinase expression in tumor invasion
J. Westermarck (1999)
Dual Regulation of Stromelysin-3 by Fibroblast Growth Factor-2 in Murine Osteoblasts*
A. Delany (1998)
Expression of Matrix Metalloproteinases during Rat Skin Wound Healing: Evidence that Membrane Type-1 Matrix Metalloproteinase Is a Stromal Activator of Pro-Gelatinase A
Akiko Okada (1997)
Discovery of CGS 27023A, a Non‐Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits.
L. Macpherson (1997)
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 195–204
R.J.J.-M. Foidart (2002)
Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer
G. Murray (1996)
Hydroxamate derivatives of substrate‐analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases 1
D. Krumme (1998)
CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading Enzymes (*)
A. Hoogewerf (1995)
Molecular design and modeling of protein-heparin interactions.
A. Cardin (1991)
Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1.
R. Khokha (1994)
Regulation of tissue inhibitor of metalloproteinases-3 gene expression by transforming growth factor-beta and dexamethasone in bovine and human articular chondrocytes.
S. Su (1996)
Activity of type IV collagenases in benign and malignant breast disease.
B. Davies (1993)
EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
N. Prenzel (1999)
Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer.
X. Lu (1991)
The Significance of Matrix Metalloproteinases during Early Stages of Tumor Progression a
A. Lochter (1998)
Matrix proteoglycans: from molecular design to cellular function.
R. Iozzo (1998)
Stromelysin-3: a paradigm for stroma-derived factors implicated in carcinoma progression.
P. Basset (1997)
Proteoglycans: structures and interactions.
L. Kjellén (1991)
Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis
O. Goldshmidt (2002)
Proteases and cancer invasion: from belief to certainty. AACR meeting on proteases and protease inhibitors in cancer, Nyborg, Denmark, 14-18 June 1998.
F. Blasi (1999)
Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
R. Montesano (1990)
Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas.
D. Muller (1993)
Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation
T. Teesalu (1999)
Of particular interest is the case of MMP-11
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed mice.
E. J. Stanbredge (1975)
Tumor necrosis factor Characterization at the molecular, cellular and in vivo level
W. Fiers (1991)
Now, however, the use of high-resolution X-ray crystallography
Disruption of epithelial cell-matrix interactions induces apoptosis
S. Frisch (1994)
Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma
Z. Dong (1997)
BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.
C. Gatto (1999)
Metalloproteinase-dependent neurite outgrowth within a synthetic extracellular matrix is induced by nerve growth factor.
D. Muir (1994)
Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase 7, matrilysin
Y. Ichikawa (2004)
Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses
B. Nawrocki (1997)
The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor
T. Watabe (1998)
Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.
M. Skobe (1998)
The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form.
H. Stanton (1998)
Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion.
H. Nakahara (1997)
Mechanisms of tumor stoma interactions with emphasis on angiogenesis and its significance for tumor growth and invasion
M. Skobe (1996)
Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinase-2 ratio in recurrence of urothelial cancer after complete resection
K Gohji (1996)
Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells.
S. Schor (1988)
Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review
P. Basset (2005)
Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor
C. Fernández-Catalán (1998)
Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs.
A. Kossakowska (1992)
Transplantation of colon carcinoma into granulation tissue induces an invasive morphotype
K. Dingemans (1993)
Substrate Specificity of Heparanases from Human Hepatoma and Platelets*
D. Pikas (1998)
Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2.
Y. DeClerck (1991)
Molecular Cloning of a Gene Encoding a New Type of Metalloproteinase-disintegrin Family Protein with Thrombospondin Motifs as an Inflammation Associated Gene*
K. Kuno (1997)
Collagenase inhibitors: their design and potential therapeutic use.
W. H. Johnson (1987)
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis
Y. Konttinen (1999)
Recent advances in matrix metalloproteinase inhibitor research
R. Becket (1996)
N-acyl peptide metalloproteinase inhibitors and methods of using the same
SS Ghosh (1991)
Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor
N. Borkakoti (1994)
Subcellular localization of heparanase in human neutrophils
Y. Matzner (1992)
Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) has erythroid‐potentiating activity
W. Stetler-Stevenson (1992)
Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain*
Y. Wang (1999)
Proteolytic remodeling of extracellular matrix.
H. Birkedal-Hansen (1995)
Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice.
D. C. Martin (1996)
Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor
I. Vlodavsky (2004)
Analysis of MT1‐MMP and MMP2 expression in human gastric cancers
M. Mori (1997)
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells.
M. Smith (1997)
Mutual induction of growth factor gene expression by epidermal-dermal cell interaction
H. Smola (1993)
Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay.
Y. Tsunezuka (1996)
Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
X. Wang (1994)
Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy.
R. Benelli (1994)
Differential modulation of epidermal keratinization in immortalized (HaCaT) and tumorigenic human skin keratinocytes (HaCaT-ras) by retinoic acid and extracellular Ca2+.
D. Breitkreutz (1993)
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
A. Docherty (1985)
Expression of Stromelysin-3 in Atherosclerotic Lesions: Regulation via CD40–CD40 Ligand Signaling In Vitro and In Vivo
U. Schönbeck (1999)
Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
H. Nakamura (1999)
Insights into MMP‐TIMP Interactions
W. Bode (1999)
Mechanism of action of a dominant-negative mutant of c-Jun.
P. Brown (1994)
Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer.
B. Tětu (1998)
Organotypic keratinocyte cocultures in defined medium with regular epidermal morphogenesis and differentiation.
H. J. Stark (1999)
Membrane Type Matrix Metalloproteinase 1 Activates Pro-gelatinase A without Furin Cleavage of the N-terminal Domain*
J. Cao (1996)
Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
W. Stetler-Stevenson (1993)
Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
S. Odake (1994)
Coordinate enhancement of gelatinase a mRNA and activity levels in human fibroblasts in response to breast‐adenocarcinoma cells
A. Noël (1994)
L. Johnson (1998)
The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A
G. Butler (1998)
Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer
S. Zucker (1993)
Structure of the human TIMP-3 gene and its cell cycle-regulated promoter.
M. Wick (1995)
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
W. Stetler-Stevenson (1999)
Heparanase expression in primary and metastatic pancreatic cancer.
A. Koliopanos (2001)
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.
G. Goldberg (1992)
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
M. Bols (1992)
The Specificity of TIMP-2 for Matrix Metalloproteinases Can Be Modified by Single Amino Acid Mutations*
G. Butler (1999)
Matrix metalloproteinase‐2 in blood does not indicate the progression of prostate cancer
K. Jung (1998)
Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases.
Y. DeClerck (1992)
c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy.
P. Boukamp (1990)
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.
Y. Friedmann (2000)
Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage
D. Pei (1999)
CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration
I. Okamoto (1999)
Modulation of human stromelysin 3 promoter activity and gene expression by human breast cancer cells
A. Ahmad (1997)
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer
K. Jung (1997)
The Phosphorylation Status of a Cyclic AMP-Responsive Activator Is Modulated via a Chromatin-Dependent Mechanism
L. Michael (2000)
Rat stromelysin 3: cDNA cloning from healing skin wound, activation by furin and expression in rat tissues.
A. Okada (1997)
Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue‐type plasminogen activator gene
P. Merchiers (1999)
TYPE IV COLLAGENASE IMMUNOREACTIVITY IN INVASIVE BREAST CARCINOMA
S. Barsky (1983)
Continuous and widespread roles for the Swi–Snf complex in transcription
S. Biggar (1999)
High level of MT‐MMP expression is associated with invasiveness of cervical cancer cells
C. Gilles (1996)
Transcriptional activation of cathepsin D gene expression by growth factors.
F. Wang (2000)
Complex role of matrix metalloproteinases in angiogenesis
Q. X. Sang (1998)
Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study
Oliver Brummer (1999)
Heparanase and a Synthetic Peptide of Heparan Sulfate-interacting Protein Recognize Common Sites on Cell Surface and Extracellular Matrix Heparan Sulfate*
D. Marchetti (1997)
Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
A. W. Millar (1998)
Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts.
M. Brauchle (1994)
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
SE Zook (1997)
High levels of TIMP‐2 correlate with adverse prognosis in breast cancer
A. Remacle (2000)
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
V. Macaulay (1999)
Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases.
K. J. Bame (1998)
c-Jun and JunB Antagonistically Control Cytokine-Regulated Mesenchymal–Epidermal Interaction in Skin
A. Szabowski (2000)
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.
H. Dvorak (1986)
Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
H. Ueno (1997)
Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia.
W. Monsky (1993)
Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun
R. Chiu (1989)
TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads*
T. Kinoshita (1998)
Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation
V. Knäuper (1996)
Three proteins define a class of human histone deacetylases related to yeast Hda1p.
C. Grozinger (1999)
Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway.
M. Hosaka (1991)
Proteolysis and cell migration: creating a path?
G. Murphy (1999)
Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
T. J. Delebecq (2000)
Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases.
B. Bertaux (1991)
Changing views of the role of matrix metalloproteinases in metastasis.
A. Chambers (1997)
Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer
G. Murray (1998)
The collagenase gene promoter contains a TPA and oncogene‐responsive unit encompassing the PEA3 and AP‐1 binding sites.
A. Gutman (1990)
Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells.
R. Khokha (1989)
showed that the adenovirus E1A protein
The regulation of AP-1 activity by mitogen-activated protein kinases.
M. Karin (1996)
Heparanases and tumor metastasis
M. Nakajima (1988)
Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4
M. Wang (1997)
In vivo analysis of the state of the human uPA enhancer following stimulation by TPA
I. Ibañez-Tallon (1999)
Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
S. Ylisirniö (2000)
Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.
S. Cowell (1998)
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
D. Grignon (1996)
Presence of high levels of MT1‐MMP protein in fibroblastic cells of human invasive carcinomas
M. Chenard (1999)
Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ
Z. Chang (2000)
Matrix metalloproteinases and the development of cancer.
L. Coussens (1996)
A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
P. Basset (1990)
Differential expression of matrix metalloproteinases and their inhibitors in non‐small cell lung cancer
P. Thomas (2000)
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
A. Remacle (1998)
A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells.
S. Gallea-Robache (1997)
Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences (*)
R. Gum (1996)
Processing of the Human Heparanase Precursor and Evidence That the Active Enzyme Is a Heterodimer*
M. Fairbanks (1999)
Density-dependent modulation of synthesis of keratins 1 and 10 in the human keratinocyte line HACAT and in ras-transfected tumorigenic clones.
C. Ryle (1989)
The compound’s utility is further limited by poor water solubility, which requires intraperitoneal administration
oral bioavailability (1998)
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
J. F. Wößner (1991)
Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host.
P. Soloway (1996)
Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells.
M. del Mar Barbacid (1998)
Prognostic values of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 expression in bladder cancer
Hiro-omi Kanayama (1998)
Expression of matrix metalloproteinases (MMP‐2 and ‐9) and tissue inhibitors of metalloproteinases (TIMP‐1 and ‐2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells
A. Janowska-Wieczorek (1999)
Chemokines Take Center Stage in Inflammatory Ills
T. Gura (1996)
The role of the C-terminal domain in collagenase and stromelysin specificity.
G. Murphy (1992)
Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof
H Tschesche (2000)
Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer.
M. Stearns (1996)
Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells.
L. Guédez (1998)
Tissue Inhibitor of Metalloproteinase-2 Stimulates Fibroblast Proliferation via a cAMP-dependent Mechanism (*)
M. Corcoran (1995)
Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence
D. Visscher (1994)
Cell Interaction and Epithelial Differentiation
N. Maas-Szabowski (2002)
Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
S. Watson (1996)
Programmed cell death and the control of cell survival: lessons from the nervous system.
M. Raff (1993)
Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas.
A. Okada (1995)
Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.
A. Ahmad (1998)
Unaltered Secretion of β-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient Mice*
T. Itoh (1997)
Demonstration and characterization of the angiogenic properties of cervical dysplasia.
K. Smith-McCune (1994)
Stromelysin-3 gene expression in human cancer: an overview.
N. Rouyer (1994)
Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils.
F. Mollinedo (1997)
Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene.
J. Bian (1996)
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size
J. Abe (1999)
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
J. Codony-Servat (1999)
Tissue inhibitors of matrix metalloendopeptidases.
G. Murphy (1995)
The expression pattern of thyroid hormone response genes in remodeling tadpole tissues defines distinct growth and resorption gene expression programs.
D. Berry (1998)
Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma.
H. Yamamoto (1999)
The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
X. Xing (2000)
Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis.
Y. Sugiura (1998)
Requirement for Matrix Metalloproteinase Stromelysin-3 in Cell Migration and Apoptosis during Tissue Remodeling in Xenopus laevis
A. Ishizuya-Oka (2000)
MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.
S. Afzal (1998)
Insulin-like growth factors and their binding proteins: biological actions.
J. I. Jones (1995)
The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity.
Y. C. Ko (1997)
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
G. Taraboletti (1995)
Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases‐3 (TIMP‐3)‐encoding gene
Y. Zeng (1998)
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
I. Versteege (1998)
c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK
Tiliang Deng (1994)
Competitive inhibition of human skin collagenase by N-benzyloxycarbonyl-L-prolyl-L-alanyl-3-amino-2-oxopropyl-L-leucyl-L- alanylglycine ethyl ester.
D. A. Wallace (1986)
Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.
M. Nakada (1999)
Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor.
Y. DeClerck (1991)
Integrin and basement membrane normalization in mouse grafts of human keratinocytes--implications for epidermal homeostasis.
D. Breitkreutz (1997)
In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.
L. Guédez (1998)
Heparanase: a key enzyme involved in cell invasion.
C. Parish (2001)
Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
M. Valter (1999)
The regulation of neovascularization of matrix metalloproteinases and their inhibitors.
M. Moses (1997)
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
O. R. Santos (2004)
Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH
D. Gilat (1995)
Essential roles of retinoic acid signaling in interdigital apoptosis and control of BMP-7 expression in mouse autopods.
V. Dupé (1999)
Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides
H. Q. Miao (1999)
Oligosaccharides generated by an endoglucuronidase are intermediates in the intracellular degradation of heparan sulfate proteoglycans.
L. Kjellén (1985)
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity.
G. Murphy (1991)
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
R. Black (1997)
Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase
A. Strongin (1995)
Social controls on cell survival and cell death
M. Raff (1992)
Regulation and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse ovary during gonadotropin-induced ovulation.
A. Hägglund (1999)
Extracellular Matrix Regulates Apoptosis in Mammary Epithelium through a Control on Insulin Signaling
N. Farrelly (1999)
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?
I. Vlodavsky (1991)
Human membrane type‐4 matrix metalloproteinase (MT4‐MMP) is encoded by a novel major transcript: isolation of complementary DNA clones for human and mouse mt4‐mmp transcripts
M. Kajita (1999)
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes.
R. Ward (1991)
Suramin. A potent inhibitor of melanoma heparanase and invasion.
M. Nakajima (1991)
Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor.
B. Lovejoy (1994)
Reprogramming of TIMP‐1 and TIMP‐3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines
M. Bugno (1999)
Three-dimensional structure of cyclohexapeptides containing a phosphinic bond in aqueous solution: a template for zinc metalloprotease inhibitors. A NMR and restrained molecular dynamics study.
P. Cuniasse (1995)
Dr. Josef Steiner Cancer Research Prize Lecture: The role of physiological cell death in neoplastic transformation and in anti‐cancer therapy
A. Strasser (1999)
Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development.
L. Blavier (1997)
Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.
E. J. Jacobsen (1999)
The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family.
H. V. Van Wart (1990)
Sustained nontumorigenic phenotype correlates with a largely stable chromosome content during long‐term culture of the human keratinocyte line HaCaT
P. Boukamp (1997)
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.
C. Wolf (1993)
Malignant cancer cells are characterized by their ability to invade
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
S. Wojtowicz-Praga (1998)
Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity
B. Finzel (1998)
Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas
A. Kossakowska (1999)
MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis.
H. Kinoh (1996)
The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase.
G. Murphy (1993)
Serum metalloproteinases and their inhibitors: markers for malignant potential.
T. Baker (1994)
Enzymatic degradation of glycosaminoglycans.
S. Ernst (1995)
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance.
S. Bates (1988)
Expression of stromelysin-3 in the human placenta and placental bed.
E. Maquoi (1997)
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
AF Olumi (2000)
reported a lower mortality in cancer patients
nant melanoma cells
RE Weiss (1999)
There are conflicting data on the requirement for this processing
Halting angiogenesis suppresses carcinoma cell invasion
M. Skobe (1997)
Membrane‐type 6 matrix metalloproteinase (MT6‐MMP, MMP‐25) is the second glycosyl‐phosphatidyl inositol (GPI)‐anchored MMP
S. Kojima (2000)
Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution.
A. Tuuttila (1998)
Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction.
E. Lubberts (1999)
Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
A. M. Montgomery (1993)
Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts.
I. C. Anderson (1995)
Fibroblast‐directed expression and localization of 92‐kDa type IV collagenase along the tumor‐stroma interface in an in vitro three‐dimensional model of human squamous cell carcinoma
A. H. Borchers (1997)
Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy
Michio Hoshi (2000)
The Matrix Metalloproteinase-14 (MMP-14) Gene Is Structurally Distinct from Other MMP Genes and Is Co-expressed with the TIMP-2 Gene during Mouse Embryogenesis*
S. Apte (1997)
Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma.
X. S. Puente (1996)
Defects of basement membrane and hemidesmosome structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts.
P. Tomakidi (1999)
Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements.
A. R. Farina (1999)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
D. Hanahan (1996)
Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice.
K. Morikawa (1988)
The Transcription Factors Sp1, Sp3, and AP-2 Are Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells*
H. Qin (1999)
Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study.
A. Karameris (1997)
Paracrine Regulation of Matrix Metalloproteinase Expression in the Normal Human Endometrium
K. Osteen (1999)
Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1
David C. Martin (1999)
Stromelysin‐3 (ST‐3): immunohistochemical characterization of the matrix metalloproteinase (MMP)‐11 in benign and malignant skin tumours and other skin disorders
MATRIX METALLOPROTEINASE‐2 (72 kD TYPE IV COLLAGENASE) EXPRESSION OCCURS IN THE EARLY STAGE OF HUMAN MELANOCYTIC TUMOUR PROGRESSION AND MAY HAVE PROGNOSTIC VALUE
A. Väisänen (1996)
Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules*
E. Ohuchi (1997)
Regulation of urokinase‐type plasminogen activator expression by an ERK1‐dependent signaling pathway in a squamous cell carcinoma cell line
E. Lengyel (1996)
Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts.
L. Nadav (2002)
The role of fibroblasts in tumor behavior
M. Grégoire (2004)
Angiogenic switch occurs late in squamous cell carcinomas of human skin
S. Strieth (2000)
Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.
H. Sato (1993)
Transcriptional Induction of Stromelysin-3 in Mesodermal Cells Is Mediated by an Upstream CCAAT/Enhancer-binding Protein Element Associated with a DNase I-hypersensitive Site*
D. Luo (1999)
Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum
T. Hayakawa (1992)
Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells.
G. Li (1999)
Regulation of matrix metalloproteinase-2(gelatinase A, MMP-2), membrane-type matrixmetalloproteinase-1 (MT1-MMP) and tissue inhibitorof metalloproteinases-2 (TIMP-2) expression byelastin-derived peptides in human HT-1080 fibrosarcoma cell line
B. Brassart (2004)
Furin-dependent intracellular activation of the human stromelysin-3 zymogen
D. Pei (1995)
MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover
K. Holmbeck (1999)
Purification of human collagenases with a hydroxamic acid affinity column.
W. M. Moore (1986)
Growth behaviour of normal and transformed mouse epidermal cells after reimplantation in vivo
NE Fusenig (1980)
Mobility shifting experiments on nuclear extracts of a high
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 151–168
R.J.J.-M. Foidart (2002)
Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix
N. Boudreau (1995)
Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response.
K. Heppner (1996)
Phosphonopeptides with collagenase inhibiting activity
RE Markwell (1993)
Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
T. Yoshikawa (2000)
Eukaryotic transcriptional control
R. Kornberg (1999)
Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis.
B. Holtz (1999)
Inhibitors of angiogenesis enter phase III testing.
N. Nelson (1998)
Serum matrix metalloproteinase‐2 and its density in men with prostate cancer as a new predictor of disease extension
K. Gohji (1998)
Stromelysin-3 in the biology of the normal and neoplastic mammary gland
M. Rio (2005)
Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA.
S. Matsumoto (1997)
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues.
K. Leco (1994)
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation.
H. R. Lijnen (1999)
92 kDa type IV collagenase (MMP‐9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer
B. Nielsen (1996)
The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.
W. Stetler-Stevenson (1989)
MT-MMP expression and localisation in human lung and breast cancers
M. Polette (2004)
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.
S. Vassiliou (1999)
Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
I. Vlodavsky (1999)
[Studies on collagenase inhibitors. II. Inhibitory effects of anthraquinones on bacterial collagenase].
T. Tanaka (1990)
Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes
N. Fusenig (1998)
Murine tissue inhibitor of metalloproteinases—4 (Timp—4): cDNA isolation and expression in adult mouse tissues 1
K. Leco (1997)
Stromelysin-3 mRNA expression in dysplasias and invasive epithelial cancer of the larynx.
E. Munck-Wikland (1998)
Transcriptional Induction of Collagenase-1 in Differentiated Monocyte-like (U937) Cells is Regulated by AP-1 and an Upstream C/EBP-β Site*
G. Doyle (1997)
The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*)
J. Whitelock (1996)
Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance*
M. O'Reilly (1999)
Lysolecithin-induced Alteration of Subendothelial Heparan Sulfate Proteoglycans Increases Monocyte Binding to Matrix (*)
P. Sivaram (1995)
Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.
G. Velasco (2000)
The generation of endostatin is mediated by elastase.
W. Wen (1999)
Syntheses and HPLC Separation of Chiral 1,3,4-Thiadiazines and 1,3,4- Selenadiazines.
T. Jira (1994)
metastasis by sulphated polysaccharides
G. David (1987)
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis.
I. Vlodavsky (1983)
Stromelysin-3 expression in noninvasive and invasive neoplasms of the urinary bladder.
J. Müller (2000)
Expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and the Matrix Metalloproteinase-2 in Bronchopulmonary and Breast Lesions
S. Caudroy (1999)
Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line
B. Himelstein (1997)
Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplants.
D. Breitkreutz (1998)
Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene.
J. Lohi (2000)
Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5
N. Koshikawa (2000)
‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression
J. R. Macdougall (1999)
Preclinical and Clinical Studies of MMP Inhibitors in Cancer
A. Drummond (1999)
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
C. Pyke (1991)
The Crystal Structures of 2-Isopropylamino-6-methyl-5-phenyl-6H-1,3,4-thiadiazine and 2-Isopropylamino-6-methyl-5-phenyl-6H-1,3,4-selenadiazine.
K. Szulzewsky (1993)
Epithelial-mesenchymal interactions regulate keratinocyte growth and differentiation in vitro
NE Fusenig (1994)
A fourth mechanism of action is on angiogenesis
Diverse cell surface
J Arribas (1998)
the level of invasion in malignant melanomas
OA Alvarez (1999)
Matrix-metalloproteinases in bronchopulmonary carcinomas.
C. Martinella-Catusse (1999)
ATP-Dependent Chromatin-Remodeling Complexes
M. Vignali (2000)
Peptides with collagenase inhibiting activity
RE Markwell (1989)
Matrix metalloproteinase inhibitors 1998
R. Beckett (1998)
ECM signalling: orchestrating cell behaviour and misbehaviour.
M. Lukashev (1998)
Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors.
R. Kannan (1999)
Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
A. König (1998)
High levels of tissue inhibitor of metalloproteinase‐1 predict poor outcome in patients with breast cancer
K. McCarthy (1999)
Transcriptional activation of the matrix metalloproteinase gene stromelysin-3 coincides with thyroid hormone-induced cell death during frog metamorphosis.
D. Patterton (1995)
Gene Trapping Identifies Inhibitors of Oncogenic Transformation
T. Andreú (1998)
Molecular Cloning of Mouse Tissue Inhibitor of Metalloproteinases-3 and Its Promoter
Y. Sun (1995)
Epithelial-stromal interactions modulating penetration of matrigel membranes by HPV 16-immortalized keratinocytes.
M. A. Turner (1997)
Demonstration in vivo that stromelysin-3 functions through its proteolytic activity
A. Noël (2000)
Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src
H. Allgayer (1999)
Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
A. Oberg (2000)
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.
Z. Zhou (2000)
Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
I. Vlodavsky (1994)
Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
P. Brown (1993)
The NMR structure of the inhibited catalytic domain of human stromelysin–1
P. Gooley (1994)
TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo *
Z. Wang (2000)
Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state.
A. L. Gall (2001)
Insulin-like growth factor binding protein (IGFBP) substrate zymography. A new tool to identify and characterize IGFBP-degrading proteinases.
J. Fowlkes (1997)
Binding of Active (57 kDa) Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) to Tissue Inhibitor of Metalloproteinase (TIMP)-2 Regulates MT1-MMP Processing and Pro-MMP-2 Activation*
S. Hernandez-Barrantes (2000)
A novel complex between the p65 subunit of NF‐kappa B and c‐Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene.
S. K. Hansen (1992)
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
Franz-Xaver Gomis-R¨th (1997)
Membrane Type 4 Matrix Metalloproteinase (MT4-MMP, MMP-17) Is a Glycosylphosphatidylinositol-anchored Proteinase*
Y. Itoh (1999)
Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor.
F. Grams (1995)
Recent advances in matrix metalloproteinase inhibitors research.
M. Michaelides (1999)
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 225–252
R.J.J.-M. Foidart (2002)
a suppressor role in kidney, brain, and other human cancers
AH Baker (1999)
Freeman and Parish, 1998) determined the IC50 for a variety
Thiol-based inhibitors of mammalian collagenase. Substituted amide and peptide derivatives of the leucine analogue, 2-[(R,S)-mercaptomethyl]-4-methylpentanoic acid.
K. Darlak (1990)
Structure-function relationships of the PEA3 group of Ets-related transcription factors.
Y. D. Launoit (1997)
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
U. Reuning (1995)
TIMP‐2, Over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75, 246–253 (1998)
P. Valente (1998)
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas
P. Forsyth (1999)
Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor.
Y. Wang (2000)
Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors.
E. Llano (1999)
Engineering of Selective TIMPs
H. Nagase (1999)
Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3
K. Hotary (2000)
A Non-antibacterial Chemically-modified Tetracycline Inhibits Mammalian Collagenase Activity
L. Golub (1987)
Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis
K. Newell (1994)
Localization of the Functional Domains of Human Tissue Inhibitor of Metalloproteinases-3 and the Effects of a Sorsby’s Fundus Dystrophy Mutation*
K. P. Langton (1998)
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
M. Holten-Andersen (1999)
Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2.
K. Somasundaram (1996)
Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation
A. Murphy (1993)
Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer.
D. De Cesare (1995)
Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion.
S. Imren (1996)
Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2*
W. English (2000)
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.
I. Vlodavsky (2001)
Transcriptional Activation of the Integrated Chromatin-Associated Human Immunodeficiency Virus Type 1 Promoter
A. el Kharroubi (1998)
A but these levels did not predict survival
with Dukes (2000)
showed that the PEA3/AP-1 element at –1965
Stromelysin 3: an independent prognostic factor for relapse-free survival in breast cancer represents a tumor-induced host response
A Ahmad (1998)
The variable results obtained with this approach may be partly
ECM and Cell Surface Proteolysis: Regulating Cellular Ecology
Z. Werb (1997)
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities.
Y. Xue (1998)
Identification of an inhibitor of neovascularization from cartilage.
M. Moses (1990)
Misregulation of Stromelysin-1 Expression in Mouse Mammary Tumor Cells Accompanies Acquisition of Stromelysin-1-dependent Invasive Properties*
A. Lochter (1997)
Expression Pattern and Secretion of Human and Chicken Heparanase Are Determined by Their Signal Peptide Sequence*
O. Goldshmidt (2001)
The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity.
S. Schnierer (1993)
The C-terminal Region of Membrane Type Matrix Metalloproteinase Is a Functional Transmembrane Domain Required for Pro-gelatinase A Activation (*)
J. Cao (1995)
Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.
I. Vlodavsky (1992)
Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases.
M. Santavicca (1996)
Expression of membrane-type matrix metalloproteinase in human gastric carcinomas.
Hiroshi Nomura (1995)
Matrix metalloproteinases in tumour invasion and metastasis
S. Curran (1999)
Developmental expression of tissue inhibitor of metalloproteinase (TIMP) RNA.
S. Nomura (1989)
Tissue Inhibitor of Metalloproteinases-3 Inhibits Shedding of L-selectin from Leukocytes*
G. Borland (1999)
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
E. Lengye (1995)
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
I. Cornil (1991)
v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
H. Sato (1993)
Stromelysin-3 expression promotes tumor take in nude mice.
A. Noël (1996)
Multiple Regulatory Elements in the Murine Stromelysin-3 Promoter
M. Ludwig (2000)
Mammalian heparanase as mediator of tumor metastasis and angiogenesis.
I. Vlodavsky (2000)
Matrix metalloproteinases: biologic activity and clinical implications.
A. Nelson (2000)
Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes
H. Porte (1995)
Basement membrane formation by malignant mouse keratinocyte cell lines in organotypic culture and transplants: correlation with degree of morphologic differentiation
J. Hornung (2004)
Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis
Kathleen J. Heppner Goss (1998)
A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer.
G. Tierney (1999)
Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment.
W. Stetler-Stevenson (1991)
Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design.
E. Gavuzzo (2000)
Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP‐1 and TIMP‐2)
K. Yamashita (1996)
Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity
P. Brooks (1998)
Breast-cancerassociated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing
C Wolf (1992)
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 169–194
R.J.J.-M. Foidart (2002)
The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
M. Sternlicht (2000)
Murine Matrix Metalloproteinase 9 Gene
C. Munaut (1999)
Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
Renato G. S. Chirvi (1994)
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
J. Nemunaitis (1998)
Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts.
W. Q. Zhao (1998)
Purification and properties of human platelet heparitinase.
G. Oosta (1982)
RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.
V. Dive (1999)
Comparison of the heparanase enzymes from mouse melanoma cells, mouse macrophages, and human platelets
L. Graham (1996)
Increased expression of membrane type 1‐matrix metalloproteinase in head and neck carcinoma
T. Yoshizaki (1997)
Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.
G. Beattie (1998)
Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism*
B. P. Mari (1998)
TIMP1 and adverse prognosis in non-small cell lung cancer.
K. Fong (1996)
Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines*
E. Maquoi (2000)
Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*)
E. Lengyel (1995)
The matrix metalloproteinases and their inhibitors in pancreatic cancer
S. Bramhall (1997)
Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
M. Tan (1997)
Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.
J. Schröder (2001)
High Resolution Structure of the N-terminal Domain of Tissue Inhibitor of Metalloproteinases-2 and Characterization of Its Interaction Site with Matrix Metalloproteinase-3*
F. Muskett (1998)
Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma.
S. Yan (2000)
Gelatinase B/lacZ Transgenic Mice, a Model for Mapping Gelatinase B Expression during Developmental and Injury-related Tissue Remodeling*
R. Mohan (1998)
Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line.
A. M. Montgomery (1994)
Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells.
L. Ritter (1999)
Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells
A. Lochter (1997)
Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
M. A. Lombard (1998)
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
H. S. Rasmussen (1997)
Developmental expression of mouse stromelysin-3 mRNA.
O. Lefebvre (1995)
Cloning and functional expression of a human heparanase gene.
P. Kussie (1999)
Matrix metalloproteinases: multifunctional contributors to tumor progression.
L. Mccawley (2000)
Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site*
M. Suzuki (1997)
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
D. Gomez (1997)
The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis
M. Sternlicht (1999)
Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?
M. Vincenti (1994)
Mechanisms of human bladder tumor invasion: role of protease cathepsin B.
R. Weiss (1990)
Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas
北川 育秀 (1999)
Activation mechanisms of matrix metalloproteinases.
H. Nagase (1997)
Dual over‐expression pattern of membrane‐type metalloproteinase‐1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy
H. Ohtani (1996)
Matrix Metalloproteinases in Remodeling of the Normal and Neoplastic Mammary Gland
L. Rudolph-Owen (2004)
Control of angiogenesis by heparin and other sulfated polysaccharides.
J. Folkman (1992)
EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface.
H. Guo (2000)
Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells.
R. Schultz (1988)
Inhibition of intracellular degradation of proteoglycans by leupeptin in rat ovarian granulosa cells.
M. Yanagishita (1985)
Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis
M. Hulett (1999)
The Mitogen-activated Protein Kinase and JAK-STAT Signaling Pathways Are Required for an Oncostatin M-responsive Element-mediated Activation of Matrix Metalloproteinase 1 Gene Expression*
E. Korzus (1997)
Generation of Expression Plasmids for Angiostatin, Endostatin and Timp-2 for Cancer Gene Therapy
S. Indraccolo (1999)
Cell surface binding of TIMP‐2 and pro‐MMP‐2/TIMP‐2 complex
M. Emmert-Buck (1995)
Identification of Structural Determinants Controlling Human and Mouse Stromelysin-3 Proteolytic Activities (*)
A. Noël (1995)
Immunochemical localization of heparanase in mouse and human melanomas
L. Jin (1990)
Biochemical Characterization of Human Collagenase-3 (*)
V. Knäuper (1996)
MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells
H. Pulyaeva (2004)
Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity (*)
D. Pei (1996)
The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells*
S. Mañes (1999)
Human heparanase is localized within lysosomes in a stable form.
O. Goldshmidt (2002)
Differential regulation of three thyroid hormone‐responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis
S. Damjanovski (2000)
Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage.
R. Greenwald (1992)
Structural properties of matrix metalloproteinases
W. Bode (1999)
Critical factors in the biology of human cancer metastasis.
I. Fidler (1995)
Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2.
A. Strongin (1993)
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
T. Yoneda (1997)
Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.
T. Nakamura (1997)
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
T. Itoh (1998)
Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth.
S. Koop (1994)
Attenuation of Oxidant‐Induced Lung Injury by the Synthetic Matrix Metalloproteinase Inhibitor BB‐3103
H. Foda (1999)
Synthetic inhibitors of bacterial and mammalian interstitial collagenases.
M. A. Schwartz (1992)
The Epithelial to Mesenchymal Transition and Metastatic Progression in Carcinoma
C. Gilles (1996)
In addition to the previously reported
propeptide Yana (2000)
Among the four members of the mammalian subtil
Structure-based design of MMP inhibitors: discovery and development of AG-3340
SL Bender (1997)
Phosphinic acid derivatives of steroids as 5-alpha-reductase inhibitors.
D. Holt (1989)
[Apoptosis in the pathogenesis and treatment of disease].
L. Benítez-Bribiesca (1995)
Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor.
S. Aho (1997)
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.
J. R. Macdougall (1995)
Differential effects of the anti‐inflammatory compounds heparin, mannose‐6‐phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets
M. Bartlett (1995)
Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies.
E. Wu (1997)
A Synergistic Interaction of Transcription Factors AP2 and YB-1 Regulates Gelatinase A Enhancer-dependent Transcription*
P. Mertens (1998)
Regulation of tPA in endothelial cells exposed to cyclic strain: role of CRE, AP-2, and SSRE binding sites.
B. Sumpio (1997)
A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses.
Y. Toh (1994)
Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)*
B. C. Patterson (1997)
Organotypic culture of outer root sheath cells from human hair follicles using a new culture device
F. Noser (2007)
Oncostatin M Stimulates c-Fos to Bind a Transcriptionally Responsive AP-1 Element within the Tissue Inhibitor of Metalloproteinase-1 Promoter*
F. Botelho (1998)
Expression of three extracellular matrix degradative enzymes in bladder cancer
K. Gohji (2001)
Membrane Type-1 Matrix Metalloprotease and Stromelysin-3 Cleave More Efficiently Synthetic Substrates Containing Unusual Amino Acids in Their P1′ Positions*
A. Mucha (1998)
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.
M. P. D’ortho (1997)
Biochemical Characterization of the Catalytic Domain of Membrane-Type 4 Matrix Metalloproteinase
H. Kolkenbrock (1999)
Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability.
F. Hubbard (1997)
In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy
R. Masson (1998)
Specific, High Affinity Binding of Tissue Inhibitor of Metalloproteinases-4 (TIMP-4) to the COOH-terminal Hemopexin-like Domain of Human Gelatinase A
H. Bigg (1997)
Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour‐cell‐derived heparanases
C. Parish (1987)
Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor.
K. Ota (1998)
There, it was reported that the NF-κB-like motif in the urokinase promoter was bound with a complex
TIMP-1 and TIMP-2
Specific methylation events contribute to the transcriptional repression of the mouse tissue inhibitor of metalloproteinases-3 gene in neoplastic cells.
W. Pennie (1999)
Unique organization and involvement of GAGA factors in transcriptional regulation of the Xenopus stromelysin-3 gene.
J. Li (1998)
A matrix metalloproteinase expressed on the surface of invasive tumour cells
H. Sato (1994)
Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms.
W. Li (1998)
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
C. Pyke (1993)
Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene*
K. Hammani (1996)
Transcriptional Regulation of Mammalian Genes in Vivo
C. L. Smith (1997)
Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts.
R. Goshen (1996)
Expression, purification and charaterization of recombinant mouse MT5‐MMP protein products
X. Wang (1999)
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
Mark D. Johnson (1994)
Expression of activated gelatinase in human invasive breast carcinoma
P. Brown (2004)
High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase.
A. Boulay (2001)
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.
P. Brooks (1996)
Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma.
C. Gilles (1997)
Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-3 gene expression in human synovial lining cells.
P. Gatsios (1996)
The rabbit gene for 92-kDa matrix metalloproteinase. Role of AP1 and AP2 in cell type-specific transcription.
M. E. Fini (1994)
Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
G. Kostoulas (1999)
Membrane-type matrix metalloproteinase-1(MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas.
T. Harada (1998)
and acute vascular damage
MW De Vouge (2000)
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 127–150
R.J.J.-M. Foidart (2002)
Matrilysin-inhibitor complexes: common themes among metalloproteases.
M. Browner (1995)
Matrix metalloproteinase inhibitors in the treatment of cancer
P. Brown (1997)
Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
M. Yamamoto (1996)
AP-1 function and regulation.
M. Karin (1997)
Plasma assay of gelatinase B:Tissue inhibitor of metalloproteinase complexes in cancer
S. Zucker (1995)
Contacts in Context: Promoter Specificity and Macromolecular Interactions in Transcription
J. Goodrich (1996)
NF-Y and Sp1 Cooperate for the Transcriptional Activation and cAMP Response of Human Tissue Inhibitor of Metalloproteinases-2*
Z. D. Zhong (2000)
Transactivation of the Urokinase-type Plasminogen Activator Receptor Gene through a Novel Promoter Motif Bound with an Activator Protein-2α-related Factor*
H. Allgayer (1999)
Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals
P. Tremble (1995)
Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts.
C. F. Singer (1999)
Tumor invasion: a consequence of destructive and compositional matrix alterations.
B. Pauli (1988)
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.
K. Lehti (1998)
Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2).
T. Hayakawa (1994)
Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
S. Parsons (1997)
Epidermal organization and differentiation of HaCaT keratinocytes in organotypic coculture with human dermal fibroblasts.
V. M. Schoop (1999)
Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity.
C. Nerlov (1991)
Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53
W. T. Loging (1999)
Human platelet heparanase: purification, characterization and catalytic activity.
C. Freeman (1998)
Inhibition of tumor invasion and metastasis by calciumspirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis
T. Mishima (2004)
Clinical Trials of a Low Molecular Weight Matrix Metalloproteinase Inhibitor in Cancer
P. Brown (1994)
16 – Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins
I. Vlodavsky (1993)
Involvement of the extracellular matrix heparan sulfate proteoglycans and heparan sulfate degrading enzymes in angiogenesis and metastasis
I Vlodavsky (1997)
Matrix metalloproteinases and diseases of the CNS
V. W. Yong (1998)
Emerging roles for proteinases in cancer.
A. Noël (1997)
HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS Inventors :
Repression of 92-kDa Type IV Collagenase Expression by MTA1 Is Mediated through Direct Interactions with the Promoter via a Mechanism, Which Is Both Dependent on and Independent of Histone Deacetylation*
C. Yan (2003)
High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma
Marie‐Pierre Chenard (1996)
The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis
O. Lefebvre (1992)
Thrombin activates transcription factors sp1, NF-kappaB, and CREB: importance of the use of phosphatase inhibitors during nuclear protein extraction for the assessment of transcription factor DNA-binding activities.
C. Edmead (1999)
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
A. Krueger (2001)
Marimastat (BB2516): Current status of development
W. Steward (1999)
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.
A. Baker (1998)
1.56 Å structure of mature truncated human fibroblast collagenase
John C. Spurlino (1994)
Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3.
D. Pei (1994)
The extracellular matrix as a cell survival factor.
J. Meredith (1993)
The Proprotein Convertases Furin and PACE4 Play a Significant Role in Tumor Progression
D. Bassi (2000)
Activation of a recombinant membrane type 1‐matrix metalloproteinase (MT1‐MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)‐2
H. Sato (1996)
Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression
Z. Werb (1989)
Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3*
S. Mañes (1997)
The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily.
C. Biswas (1995)
A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis*
M. Olive (1997)
Identification of active-site residues of the pro-metastatic endoglycosidase heparanase.
M. Hulett (2000)
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of DNA methylation.
R. H. Xing (1999)
Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin
D. Green (1992)
Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells
M. Polette (2004)
Transcription of chromatin: these are complex times.
J. Armstrong (1998)
[Significance of membrane type-1 matrix metalloproteinase expression in breast cancer].
G. Yao (2004)
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
M. Colombo (1991)
Sp1 functions in a chromatin-dependent manner to augment human alpha-globin promoter activity.
M. Pondel (1995)
Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases.
I. Yana (2000)
Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
S. Eccles (1996)
Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment.
A. Melchiori (1992)
Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells
C. Knabbe (1987)
Potential Target Found for Antimetastasis Drugs
E. Finkel (1999)
Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials
D. Shalinsky (1999)
Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line.
D. Breitkreutz (1991)
Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo.
N. Fusenig (1983)
Identification of the Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Binding Site on the Hemopexin Carboxyl Domain of Human Gelatinase A by Site-directed Mutagenesis
C. Overall (1999)
Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts.
N. Maas-Szabowski (2000)
Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter.
M. Costa (1998)
Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications
S. Zucker (1999)
Structural biochemistry and activation of matrix metalloproteases.
D. Kleiner (1993)
X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
F. Grams (1995)
Muschel (eds.), Proteases and Their Inhibitors in Cancer Metastasis, 109–124
R.J.J.-M. Foidart (2002)
Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence
DW Visscher (1994)
leukocytes, endothelial cells and platelets
halted tumor vascularization
AH Borchers (1999)
Wound repair-induced expression of a stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells.
A. Buisson (1996)
Partial purification and characterization of heparan sulfate specific endoglucuronidase.
U. Klein (1976)
This paper is referenced by
Friends or foes — bipolar effects of the tumour stroma in cancer
M. Mueller (2004)
Molecular effects of fractional carbon dioxide laser resurfacing on photodamaged human skin.
Michael J. Reilly (2010)
Distinct prognostic values and antitumor effects of tumor growth factor β1 and its receptors in gastric cancer
F. Liu (2020)
Interleukin‐6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma
Kati Räsänen (2016)